Gilles de la Tourette SyndromerTMSPPCGTNCT01043549
Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome
A study testing rTMS in people with Gilles de la Tourette Syndrome and Tics, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.
Trial summary
Repetitive transcranial stimulation (rTMS) of the posterior parietal cortex will be applied daily over five days in adult Gilles de la Tourette patients. This approach aims at reducing premonitory sensations believed to induce tics. Patients will be randomized to an active or placebo (sham) group in a crossover design. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Gilles de la Tourette Syndrome, Tics
- What is being tested?
- rTMS
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 5 participants
- Where
- 1 siteFrance
- Study dates
- Feb 2010to Sep 2012
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Gilles de la Tourette syndrome as defined by DSM IV-R
- Yale Global Tics Severity Scale (YGTSS) score between 30 et 60
- Premonitory sensations (" urge to move ")
- Affiliated to the French social security regime
- Ability to give informed consent
Who cannot join
- rTMS : epilepsy, craniotomy scar, pacemaker or neural stimulator, metal implants or foreign bodies, claustrophobia, pregnancy
- Cognitive impairment (MMS ≤ 24/30)
- Axis I disorders according to DSM IV-R : psychosis or history of psychosis, bipolar illness, major depressive disorder, addictions (except to nicotine)
- Impulse control disorders
- Other chronic debilitating illnesses
- Unability to give informed consent
- Participation in another clinical trial
Trial locations and contacts
1 site in 1 country.
About this study
Repetitive transcranial stimulation (rTMS) of the posterior parietal cortex will be applied daily over five days in adult Gilles de la Tourette patients. This approach aims at reducing premonitory sensations believed to induce tics. Patients will be randomized to an active or placebo (sham) group in a crossover design.
- Conditions
- Gilles de la Tourette Syndrome, Tics
- Being tested
- rTMS, Sham rTMS
- Keywords
- Gilles de la Tourette syndrome, Tics, Transcranial magnetic stimulation
- Medical subject headings
- Tourette Syndrome, Tics
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
rTMSDevice
Repetitive transcranial stimulation of the posterior parietal cortex
Sham rTMSDevice
Repetitive transcranial stimulation of the posterior parietal cortex
| Study group | Role | What they receive |
|---|---|---|
| Stimulation | Active comparator | Repetitive transcranial stimulation of the posterior parietal cortex Receives: Device: rTMS |
| Sham stimulation | Sham comparator | Not described Receives: Device: Sham rTMS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Yale global tic severity scale (YTGSS)
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jan 2010 (estimated)
- Study startFeb 2010
- Primary completionSep 2012
- Study completionSep 2012
Why it stopped: lack of efficacy
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gilles de la Tourette SyndromeStudies of the same condition, open and under way.
- More trials run by Institut National de la Santé Et de la Recherche Médicale, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 5 participants (actual)
Sponsor and investigators
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- Andreas Hartmann, MD, Principal investigator, Institut National de la Santé Et de la Recherche Médicale, France
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01043549
- Sponsor's protocol ID
- C08-46
- Other IDs
- 2009-A00759-48
- Acronym
- rTMSPPCGT
- Status last verified
- Feb 2016
- First submitted
- 4 Jan 2010
- Last updated
- 9 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome
- ClinicalTrials.gov ID
- NCT01043549
- Acronym / sponsor ID
- rTMSPPCGT / C08-46
- Conditions
- Gilles de la Tourette Syndrome, Tics
- Keywords
- Gilles de la Tourette syndrome, Tics, Transcranial magnetic stimulation
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: lack of efficacy
- Enrolment
- 5 participants (actual)
- Lead sponsor
- Institut National de la Santé Et de la Recherche Médicale, FranceOther government
- Study start
- Feb 2010
- Primary completion
- Sep 2012 (actual)
- Study completion
- Sep 2012 (actual)
- First posted
- 6 Jan 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Repetitive transcranial stimulation (rTMS) of the posterior parietal cortex will be applied daily over five days in adult Gilles de la Tourette patients. This approach aims at reducing premonitory sensations believed to induce tics. Patients will be randomized to an active or placebo (sham) group in a crossover design.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Stimulation | Active comparator | Device: rTMSRepetitive transcranial stimulation of the posterior parietal cortex |
| Sham stimulation | Sham comparator | Device: Sham rTMS |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Gilles de la Tourette syndrome as defined by DSM IV-R
- Yale Global Tics Severity Scale (YGTSS) score between 30 et 60
- Premonitory sensations (" urge to move ")
- Affiliated to the French social security regime
- Ability to give informed consent
Key exclusion criteria (7 listed)
- rTMS : epilepsy, craniotomy scar, pacemaker or neural stimulator, metal implants or foreign bodies, claustrophobia, pregnancy
- Cognitive impairment (MMS ≤ 24/30)
- Axis I disorders according to DSM IV-R : psychosis or history of psychosis, bipolar illness, major depressive disorder, addictions (except to nicotine)
- Impulse control disorders
- Other chronic debilitating illnesses
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| rTMSRepetitive transcranial stimulation of the posterior parietal cortex | Device | Stimulation |
| Sham rTMSRepetitive transcranial stimulation of the posterior parietal cortex | Device | Sham stimulation |
Primary outcome
Yale global tic severity scale (YTGSS)
Time frame: 3 months
Results and safety
The study was stopped early (reason given: lack of efficacy). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Oct 2026.
- Related InfoLink provided by the sponsor.
Related trials for Gilles de la Tourette Syndrome
Recruiting
Integrating Exposure and Response Prevention and Habit Reversal Techniques to Treat a Tourettic Subtype of Obsessive-Compulsive Disorder (Tourettic OCD)
Obsessive - Compulsive Disorder, Tic Disorder, Chronic Motor or Vocal
Recruiting
Objective Characterizatoion of Repetitive Behaviors
OCD, Tic Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Andreas Hartmann, MD principal investigator
Institut National de la Santé Et de la Recherche Médicale, France
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing rTMS in people with Gilles de la Tourette Syndrome and Tics, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 9 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: lack of efficacy). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Yale global tic severity scale (YTGSS) (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2026.